Amgen at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

Amgen takes part in 3 sessions at ACT 2026 in San Antonio. Its sessions cover how to design an embryofetal development study and how to assess safety signals for a rare disease biotherapeutic, both ahead of time and in hindsight. It also covers how an antibody crosses the blood-labyrinth barrier into the inner ear when assessing hearing damage.

Organization	ACT 2026 Attendance
Amgen Thousand Oaks, CA
amgen.com Pharmaceutical companies Global biopharmaceutical company with marketed biologic and small-molecule medicines in oncology, inflammation, cardiovascular and bone disease.	Talk Sun Nov 15 8:05am–8:30am Part of The ABCs of EFDs: A Modern Guide to Embryofetal Development Testing (CE3) Designing a EFD Study (CE3-2) DART Talk Mon Nov 16 4:20pm–4:55pm Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06) Prospective and Retrospective Risk Assessments of Safety Signals for a Rare Disease Biotherapeutic (S06-5) Translational safety Talk Wed Nov 18 9:25am–9:50am Part of Do You Hear What I Hear? Evaluating Otic and Vestibular Toxicity in Clinical Development (S14) The Blood-Labyrinth-Barrier (BLB) and Biodistribution of a mAb into the Ear to Assess Ototoxicity (S14-2) Neurotoxicology · Biologics and new modalities

Organization

ACT 2026 Attendance

Amgen

Thousand Oaks, CA

amgen.com

Pharmaceutical companies

Global biopharmaceutical company with marketed biologic and small-molecule medicines in oncology, inflammation, cardiovascular and bone disease.

Talk

Sun Nov 15
8:05am–8:30am

Part of The ABCs of EFDs: A Modern Guide to Embryofetal Development Testing (CE3)

Designing a EFD Study (CE3-2)

DART

Talk

Mon Nov 16
4:20pm–4:55pm

Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06)

Prospective and Retrospective Risk Assessments of Safety Signals for a Rare Disease Biotherapeutic (S06-5)

Translational safety

Talk

Wed Nov 18
9:25am–9:50am

Part of Do You Hear What I Hear? Evaluating Otic and Vestibular Toxicity in Clinical Development (S14)

The Blood-Labyrinth-Barrier (BLB) and Biodistribution of a mAb into the Ear to Assess Ototoxicity (S14-2)

Neurotoxicology · Biologics and new modalities

Instantly find 20 buyers from Amgen

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction